ArticleAsian Pacific journal of cancer prevention : APJCP2024
Incidence of Epstein-Barr Virus Reactivation and Its Risk Factors in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiological Trends and Clinical Characteristics of Epstein-Barr Virus Infection in Febrile Children in Zhejiang, China: A Retrospective Study.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpstein-Barr virus (EBV) reactivation in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients can lead to significant complications including post-transplant lymphoproliferative disease. Despite progress in managing EBV reactivation in allo-HCT recipients, data on clinical characteristics and prognostic implications of EBV viral load remain limited. Here, we aim to evaluate the prevalence, identify risk factors, and assess the clinical implications of EBV-DNA positivity in allo-HCT recipients.
methodsA retrospective audit of laboratory records for EBV load monitoring in allo-HCT recipients during the period from 2021 to 2023 was performed. EBV viral load was assessed using quantitative PCR. The medical records were reviewed for clinical features, identifying risk factors, and prognostic impact of EBV-DNA positivity.
resultsA total of 40 patients with a median age of 20.5 years were included. Patients were divided into two groups based on presence (>600 copies/mL) and absence of EBV-DNA. We observed EBV-DNA positivity in 16 (40%) patients with a median EBV viral load of 12,400 copies/ml. Patients with EBV-DNA positivity exhibited a higher incidence of acute graft versus host disease (p=0.039). Patients with EBV-DNA positivity tended to have poorer 1-year overall survival and disease-free survival, although the results did not reach statistical significance.
conclusionOur data highlights the importance of monitoring EBV viral load in predicting the outcome in terms of overall survival in allo-HCT recipients. The development of GVHD has also surfaced as a significant element increasing the likelihood of EBV-DNA positivity. It is imperative to conduct further research and establish comprehensive protocols for the routine monitoring and management of EBV post-allo-HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.